Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is a long non-coding RNA transcribed in the antisense orientation to the ZNF253 gene. Long non-coding antisense transcripts frequently function via a range of gene regulatory mechanisms, including interfering with transcription, modulating mRNA stability, altering chromatin states, and affecting the expression of their sense counterparts[2][4][5]. While many antisense lncRNAs have emerging relevance in disease regulation and cell biology, there is no specific characterized function, disease linkage, or therapeutic relevance currently reported for "novel transcript, antisense to ZNF253" (ENSG00000267565)[3].
Transcriptional interference, RNA masking, Chromatin remodeling, dsRNA-dependent silencing (such as RNA interference). These are general mechanisms by which antisense transcripts regulate their corresponding sense genes, not necessarily specific to this transcript[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to ZNF253.